ABBV-085,一种靶向LRRC15的抗体-药物结合物(ADC),在肉瘤和其他进展期实体肿瘤中的首次人体一期研究 Disclosures PresentedByGeorgeDemetriat2019ASCOAnnualMeeting First-in-HumanPhase1StudyofABBV-085,anAntibody-DrugConjugate(ADC)TargetingLRRC15,inSarcomasandOtherAdvancedSolidTumors PresentedByGeorgeDemetriat2019ASCO...
16 - ABBV-085 is a novel antibody–drug conjugate (ADC) that targets LRRC15 in the tumor microenvironmentdoi:10.1016/S0959-8049(16)32622-3SDOSEuropean Journal of Cancer
anti-huLR C15 ADC ABBV-085, PR-1498487-MMAE PR-1498487 PAB-MMAE Developer AbbVie, Inc. Clinical domain Oncology Clinical indication Solid tumors in which huLRRC15 is expressed in the tumor stromal microenvironment. Development status Phase I ...